{
  "resourceType" : "PlanDefinition",
  "id" : "TherapeuticAnticoagulationNonICUHighRiskCOVID19PatientsPlan",
  "meta" : {
    "profile" : ["https://www.netzwerk-universitaetsmedizin.de/fhir/cpg-on-ebm-on-fhir/StructureDefinition/recommendation-plan"]
  },
  "text" : {
    "status" : "generated",
    "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: PlanDefinition TherapeuticAnticoagulationNonICUHighRiskCOVID19PatientsPlan</b></p><a name=\"TherapeuticAnticoagulationNonICUHighRiskCOVID19PatientsPlan\"> </a><a name=\"hcTherapeuticAnticoagulationNonICUHighRiskCOVID19PatientsPlan\"> </a><a name=\"TherapeuticAnticoagulationNonICUHighRiskCOVID19PatientsPlan-en-US\"> </a><p><b>url</b>: <a href=\"PlanDefinition-TherapeuticAnticoagulationNonICUHighRiskCOVID19PatientsPlan.html\">PlanDefinition Therapeutic Anticoagulation Plan (hospitalised, non-intensive care, COVID-19 patients</a></p><p><b>version</b>: 7.0</p><p><b>name</b>: Therapeutic_Anticoagulation_No_Renal_Function_Impairment</p><p><b>title</b>: Therapeutic Anticoagulation Plan (hospitalised, non-intensive care, COVID-19 patients</p><p><b>type</b>: <span title=\"Codes:{http://terminology.hl7.org/CodeSystem/plan-definition-type eca-rule}\">ECA Rule</span></p><p><b>status</b>: Active</p><p><b>experimental</b>: true</p><p><b>subject</b>: <a href=\"EvidenceVariable-PopHospitalisedNonICUCOVID19PatientsWITHHighRisk.html\">Population: Hospitalised COVID-19 patients without the need for intensive care therapy considered high-risk for developing venous thrombosis</a></p><p><b>date</b>: 2022-02</p><p><b>publisher</b>: NUM CODEX+ CELIDA</p><p><b>description</b>: </p><div><p>In hospitalized, non-intensive care patients with COVID-19 and increased risk (e.g., D-dimers ≥ 2 mg/l), therapeutic anticoagulation can be considered if the risk of bleeding is low. Anticoagulation, preferentially with NMH or UFH, can be considered.</p>\n</div><blockquote><p><b>goal</b></p><blockquote><p><b>id</b></p>aPTT-goal</blockquote><p><b>category</b>: <span title=\"Codes:{http://snomed.info/sct 410394004}\">Lab findings surveillance (regime/therapy)</span></p><p><b>description</b>: <span title=\"Codes:\">aPTT value should be &gt; 50 sec.</span></p><h3>Targets</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Measure</b></td><td><b>Detail[x]</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{http://loinc.org 3173-2}\">aPTT in Blood by Coagulation assay</span></td><td>50.0000001-? sec</td></tr></table></blockquote><blockquote><p><b>action</b></p><p><b>code</b>: <span title=\"Codes:{http://snomed.info/sct 432102000}\">Administration of substance (procedure)</span></p><p><b>goalId</b>: aPTT-goal</p><p><b>definition</b>: <a href=\"ActivityDefinition-TherapeuticAnticoagulationUFH.html\">Therapeutic Anticoagulation Treatment UFH</a></p></blockquote><blockquote><p><b>action</b></p><p><b>code</b>: <span title=\"Codes:{http://snomed.info/sct 432102000}\">Administration of substance (procedure)</span></p><p><b>definition</b>: <a href=\"ActivityDefinition-TherapeuticAnticoagulationNMHDalteparin1xd.html\">Therapeutic Anticoagulation Treatment with Dalteparin</a></p></blockquote><blockquote><p><b>action</b></p><p><b>code</b>: <span title=\"Codes:{http://snomed.info/sct 432102000}\">Administration of substance (procedure)</span></p><p><b>definition</b>: <a href=\"ActivityDefinition-TherapeuticAnticoagulationNMHDalteparin2xd.html\">Therapeutic Anticoagulation Treatment with Dalteparin</a></p></blockquote><blockquote><p><b>action</b></p><p><b>code</b>: <span title=\"Codes:{http://snomed.info/sct 432102000}\">Administration of substance (procedure)</span></p><p><b>definition</b>: <a href=\"ActivityDefinition-TherapeuticAnticoagulationNMHDalteparinTable.html\">Therapeutic Anticoagulation Treatment with Dalteparin</a></p></blockquote><blockquote><p><b>action</b></p><p><b>code</b>: <span title=\"Codes:{http://snomed.info/sct 432102000}\">Administration of substance (procedure)</span></p><p><b>definition</b>: <a href=\"ActivityDefinition-TherapeuticAnticoagulationNMHNadroparin.html\">Therapeutic Anticoagulation Treatment with Nadroparin</a></p></blockquote><blockquote><p><b>action</b></p><p><b>code</b>: <span title=\"Codes:{http://snomed.info/sct 432102000}\">Administration of substance (procedure)</span></p><p><b>definition</b>: <a href=\"ActivityDefinition-TherapeuticAnticoagulationNMHEnoxaparin1xd.html\">Therapeutic Anticoagulation Treatment with Enoxaparin</a></p></blockquote><blockquote><p><b>action</b></p><p><b>code</b>: <span title=\"Codes:{http://snomed.info/sct 432102000}\">Administration of substance (procedure)</span></p><p><b>definition</b>: <a href=\"ActivityDefinition-TherapeuticAnticoagulationNMHEnoxaparin2xd.html\">Therapeutic Anticoagulation Treatment with Enoxaparin</a></p></blockquote><blockquote><p><b>action</b></p><p><b>code</b>: <span title=\"Codes:{http://snomed.info/sct 432102000}\">Administration of substance (procedure)</span></p><p><b>definition</b>: <a href=\"ActivityDefinition-TherapeuticAnticoagulationNMHCertoparin.html\">Therapeutic Anticoagulation Treatment with Certoparin</a></p></blockquote><blockquote><p><b>action</b></p><p><b>code</b>: <span title=\"Codes:{http://snomed.info/sct 432102000}\">Administration of substance (procedure)</span></p><p><b>definition</b>: <a href=\"ActivityDefinition-TherapeuticAnticoagulationFondaparinux.html\">Therapeutic Anticoagulation Treatment with Fondaparinux</a></p></blockquote><blockquote><p><b>action</b></p><p><b>code</b>: <span title=\"Codes:{http://snomed.info/sct 432102000}\">Administration of substance (procedure)</span></p><p><b>goalId</b>: aPTT-goal</p><p><b>definition</b>: <a href=\"ActivityDefinition-TherapeuticAnticoagulationWArgatra.html\">Therapeutic Anticoagulation Treatment with Argatroban</a></p></blockquote><blockquote><p><b>action</b></p><p><b>code</b>: <span title=\"Codes:{http://snomed.info/sct 432102000}\">Administration of substance (procedure)</span></p><p><b>definition</b>: <a href=\"ActivityDefinition-TherapeuticAnticoagulationNMHTinzaparin.html\">Therapeutic Anticoagulation Treatment with Tinzaparin</a></p></blockquote></div>"
  },
  "extension" : [{
    "url" : "http://hl7.org/fhir/uv/cpg/StructureDefinition/cpg-knowledgeCapability",
    "valueCode" : "computable"
  },
  {
    "url" : "http://hl7.org/fhir/uv/cpg/StructureDefinition/cpg-knowledgeRepresentationLevel",
    "valueCode" : "structured"
  },
  {
    "url" : "http://hl7.org/fhir/uv/cpg/StructureDefinition/cpg-partOf",
    "valueCanonical" : "https://www.netzwerk-universitaetsmedizin.de/fhir/codex-celida/guideline/covid19-inpatient-therapy/recommendation/therapeutic-anticoagulation"
  },
  {
    "extension" : [{
      "url" : "method",
      "valueCodeableConcept" : {
        "coding" : [{
          "system" : "https://www.netzwerk-universitaetsmedizin.de/fhir/cpg-on-ebm-on-fhir/CodeSystem/cs-action-combination-method",
          "code" : "at-least"
        }]
      }
    },
    {
      "url" : "threshold",
      "valuePositiveInt" : 1
    }],
    "url" : "https://www.netzwerk-universitaetsmedizin.de/fhir/cpg-on-ebm-on-fhir/StructureDefinition/ext-action-combination-method"
  }],
  "url" : "https://www.netzwerk-universitaetsmedizin.de/fhir/codex-celida/guideline/covid19-inpatient-therapy/intervention-plan/therapeutic-anticoagulation",
  "version" : "7.0",
  "name" : "Therapeutic_Anticoagulation_No_Renal_Function_Impairment",
  "title" : "Therapeutic Anticoagulation Plan (hospitalised, non-intensive care, COVID-19 patients",
  "type" : {
    "coding" : [{
      "system" : "http://terminology.hl7.org/CodeSystem/plan-definition-type",
      "code" : "eca-rule"
    }]
  },
  "status" : "active",
  "experimental" : true,
  "subjectCanonical" : "https://www.netzwerk-universitaetsmedizin.de/fhir/codex-celida/guideline/covid19-inpatient-therapy/population/hospitalised-non-icu-covid19-patients-high-risk",
  "date" : "2022-02",
  "publisher" : "NUM CODEX+ CELIDA",
  "description" : "In hospitalized, non-intensive care patients with COVID-19 and increased risk (e.g., D-dimers ≥ 2 mg/l), therapeutic anticoagulation can be considered if the risk of bleeding is low. Anticoagulation, preferentially with NMH or UFH, can be considered.",
  "goal" : [{
    "id" : "aPTT-goal",
    "category" : {
      "coding" : [{
        "system" : "http://snomed.info/sct",
        "code" : "410394004",
        "display" : "Lab findings surveillance (regime/therapy)"
      }]
    },
    "description" : {
      "text" : "aPTT value should be > 50 sec."
    },
    "target" : [{
      "measure" : {
        "coding" : [{
          "system" : "http://loinc.org",
          "code" : "3173-2",
          "display" : "aPTT in Blood by Coagulation assay"
        }]
      },
      "detailRange" : {
        "low" : {
          "value" : 50.0000001,
          "unit" : "sec",
          "system" : "http://unitsofmeasure.org",
          "code" : "s"
        }
      }
    }]
  }],
  "action" : [{
    "code" : {
      "coding" : [{
        "system" : "http://snomed.info/sct",
        "code" : "432102000",
        "display" : "Administration of substance (procedure)"
      }]
    },
    "goalId" : ["aPTT-goal"],
    "definitionCanonical" : "https://www.netzwerk-universitaetsmedizin.de/fhir/codex-celida/guideline/covid19-inpatient-therapy/recommended-action/drug-administration-action/therapeutic-anticoagulant-UFH-administration"
  },
  {
    "code" : {
      "coding" : [{
        "system" : "http://snomed.info/sct",
        "code" : "432102000",
        "display" : "Administration of substance (procedure)"
      }]
    },
    "definitionCanonical" : "https://www.netzwerk-universitaetsmedizin.de/fhir/codex-celida/guideline/covid19-inpatient-therapy/recommended-action/drug-administration-action/therapeutic-anticoagulant-dalteparin-administration-1xd"
  },
  {
    "code" : {
      "coding" : [{
        "system" : "http://snomed.info/sct",
        "code" : "432102000",
        "display" : "Administration of substance (procedure)"
      }]
    },
    "definitionCanonical" : "https://www.netzwerk-universitaetsmedizin.de/fhir/codex-celida/guideline/covid19-inpatient-therapy/recommended-action/drug-administration-action/therapeutic-anticoagulant-dalteparin-administration-2xd"
  },
  {
    "code" : {
      "coding" : [{
        "system" : "http://snomed.info/sct",
        "code" : "432102000",
        "display" : "Administration of substance (procedure)"
      }]
    },
    "definitionCanonical" : "https://www.netzwerk-universitaetsmedizin.de/fhir/codex-celida/guideline/covid19-inpatient-therapy/recommended-action/drug-administration-action/therapeutic-anticoagulant-dalteparin-administration-table"
  },
  {
    "code" : {
      "coding" : [{
        "system" : "http://snomed.info/sct",
        "code" : "432102000",
        "display" : "Administration of substance (procedure)"
      }]
    },
    "definitionCanonical" : "https://www.netzwerk-universitaetsmedizin.de/fhir/codex-celida/guideline/covid19-inpatient-therapy/recommended-action/drug-administration-action/therapeutic-anticoagulant-nadroparin-administration"
  },
  {
    "code" : {
      "coding" : [{
        "system" : "http://snomed.info/sct",
        "code" : "432102000",
        "display" : "Administration of substance (procedure)"
      }]
    },
    "definitionCanonical" : "https://www.netzwerk-universitaetsmedizin.de/fhir/codex-celida/guideline/covid19-inpatient-therapy/recommended-action/drug-administration-action/therapeutic-anticoagulant-enoxaparin-administration-1xd"
  },
  {
    "code" : {
      "coding" : [{
        "system" : "http://snomed.info/sct",
        "code" : "432102000",
        "display" : "Administration of substance (procedure)"
      }]
    },
    "definitionCanonical" : "https://www.netzwerk-universitaetsmedizin.de/fhir/codex-celida/guideline/covid19-inpatient-therapy/recommended-action/drug-administration-action/therapeutic-anticoagulant-enoxaparin-administration-2xd"
  },
  {
    "code" : {
      "coding" : [{
        "system" : "http://snomed.info/sct",
        "code" : "432102000",
        "display" : "Administration of substance (procedure)"
      }]
    },
    "definitionCanonical" : "https://www.netzwerk-universitaetsmedizin.de/fhir/codex-celida/guideline/covid19-inpatient-therapy/recommended-action/drug-administration-action/therapeutic-anticoagulant-certoparin-administration"
  },
  {
    "code" : {
      "coding" : [{
        "system" : "http://snomed.info/sct",
        "code" : "432102000",
        "display" : "Administration of substance (procedure)"
      }]
    },
    "definitionCanonical" : "https://www.netzwerk-universitaetsmedizin.de/fhir/codex-celida/guideline/covid19-inpatient-therapy/recommended-action/drug-administration-action/therapeutic-anticoagulant-fondaparinux-administration"
  },
  {
    "code" : {
      "coding" : [{
        "system" : "http://snomed.info/sct",
        "code" : "432102000",
        "display" : "Administration of substance (procedure)"
      }]
    },
    "goalId" : ["aPTT-goal"],
    "definitionCanonical" : "https://www.netzwerk-universitaetsmedizin.de/fhir/codex-celida/guideline/covid19-inpatient-therapy/recommended-action/drug-administration-action/therapeutic-anticoagulant-argatroban-administration"
  },
  {
    "code" : {
      "coding" : [{
        "system" : "http://snomed.info/sct",
        "code" : "432102000",
        "display" : "Administration of substance (procedure)"
      }]
    },
    "definitionCanonical" : "https://www.netzwerk-universitaetsmedizin.de/fhir/codex-celida/guideline/covid19-inpatient-therapy/recommended-action/drug-administration-action/therapeutic-anticoagulant-tinzaparin-administration"
  }]
}